Special Issue

Selective Chelators for Metals on Cells and Cancer Chemotherapy

Message from the Guest Editor

Cancer research continues to be one of the leading banners in medicine and the pharmaceutical sciences. Since this is a topic of great interest to society, the fields of knowledge that act directly in the fight against this disease are numerous and are transversal to different central sciences, such as chemistry, physics or biology. In this context, there are several types of treatments applied for cancer eradication, with chemotherapy procedures leading the way. Besides, the designation of cancer chemotherapy by yourself is quite broad, comprising a large number of medicines and medical practices. One of the approaches used to combat cancer cell proliferation is based on the application of molecules with chelating / ligand properties, selective for different metals in cell media. In this context, the present special Issue aims to combine a collection of original and review articles comprising basic science, preclinical and clinical discoveries that embrace metalchelating compounds for cancer chemotherapy.

Guest Editor

Dr. Luís M. T. Frija

Centro de Química Estrutural, Instituto Superior Técnico—Universidade de Lisboa, Lisbon, Portugal

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/40795

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

